Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 QTc Assessment in Acute Leukemias and MDS
NCT02238925Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jul 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Cardiac Ventricular Repolarization (QTcF) at 21 days. Started Jul 2014; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02238925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238925.